Viatris’Mylan may face a battle to hold onto a recent favorable verdict from the US Court of Appeals for the Federal Circuit that breathed new life into the firm potentially circumventing AstraZeneca’s intellectual property shielding its blockbuster Symbicort (budesonide/formoterol fumarate dihydrate) pressurized metered dose inhaler.
The UK-based originator has petitioned the Federal Circuit for panel rehearing or rehearing en banc of its recent 2-1 split...